{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:23:46Z","timestamp":1773419026838,"version":"3.50.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20ck0106585"],"award-info":[{"award-number":["JP20ck0106585"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23ck0106895"],"award-info":[{"award-number":["JP23ck0106895"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Cancer Center Research and Development Fund","award":["2020-J-3"],"award-info":[{"award-number":["2020-J-3"]}]},{"name":"National Cancer Center Research and Development Fund","award":["2023-J-03"],"award-info":[{"award-number":["2023-J-03"]}]},{"name":"Japan Society of Clinical Oncology and the National Federation of Health Insurance Societies"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint blockades (ICBs), particularly PD-1 pathway blockades, have significantly improved outcomes in advanced renal cell carcinoma (RCC). However, long-term ICB therapy imposes substantial financial and toxicity burdens. Retrospective data suggest that treatment responses plateau around 24\u00a0weeks, and some patients maintain disease control even after ICB pause. We initiated a multi-institutional, open-label, randomized controlled trial to confirm the non-inferiority of pausing PD-1 pathway blockade to its continuous administration in patients with advanced clear cell RCC without disease progression. The primary endpoint is overall survival and the secondary endpoint includes time to failure of strategy, progression-free survival, and adverse events. Conducted by the Urologic Oncology Study Group of the Japan Clinical Oncology Group (JCOG), this phase III trial was approved by Certified Review Board in February 2020, with patient enrollment beginning in July 2020. The trial is registered in the Japan Registry for Clinical Trials (JCOG1905; jRCT1031200071).<\/jats:p>","DOI":"10.1093\/jjco\/hyaf190","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T13:09:21Z","timestamp":1762952961000},"page":"352-357","source":"Crossref","is-referenced-by-count":0,"title":["A randomized controlled phase III trial on continued or paused PD-1 pathway blockade for patients with advanced renal cell carcinoma (JCOG1905, STOP study): a study protocol"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1570-6340","authenticated-orcid":false,"given":"Takashi","family":"Matsumoto","sequence":"first","affiliation":[{"name":"Department of Urology, Graduate School of Medical Sciences, Kyushu University , Fukuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tokiyoshi","family":"Tanegashima","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical Sciences, Kyushu University , Fukuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ario","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical Sciences, Kyushu University , Fukuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5100-3863","authenticated-orcid":false,"given":"Keita","family":"Sasaki","sequence":"additional","affiliation":[{"name":"JCOG Data Center\/Operation Office, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gakuto","family":"Ogawa","sequence":"additional","affiliation":[{"name":"JCOG Data Center\/Operation Office, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4150-9631","authenticated-orcid":false,"given":"Takahiro","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Urology, Aichi Cancer Center Hospital , Nagoya ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kawahara","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Tsukuba , Tsukuba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Urology and Retroperitoneal Surgery, National Cancer Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naotaka","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Toyama , Toyama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Tsukuba , Tsukuba ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Toyama , Toyama ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Eto","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical Sciences, Kyushu University , Fukuoka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"2026031310015434700_ref1","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"2026031310015434700_ref2","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.annonc.2024.07.727","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial","volume":"35","author":"Tannir","year":"2024","journal-title":"Ann Oncol"},{"key":"2026031310015434700_ref3","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"2026031310015434700_ref4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"2026031310015434700_ref5","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"2026031310015434700_ref6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur Urol"},{"key":"2026031310015434700_ref7","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1093\/annonc\/mdx151","article-title":"Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions","volume":"28","author":"Atkins","year":"2017","journal-title":"Ann Oncol"},{"key":"2026031310015434700_ref8","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026031310015434700_ref9","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of Nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026031310015434700_ref10","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","article-title":"Durable complete response after discontinuation of Pembrolizumab in patients with metastatic melanoma","volume":"36","author":"Robert","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026031310015434700_ref11","doi-asserted-by":"publisher","first-page":"e003473","DOI":"10.1136\/jitc-2021-003473","article-title":"Treatment-free survival after discontinuation of immune checkpoint inhibitors in metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"9","author":"Tzeng","year":"2021","journal-title":"J Immunotherap Cancer"},{"key":"2026031310015434700_ref12","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/jjco\/hyx049","article-title":"Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study","volume":"47","author":"Tomita","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"2026031310015434700_ref13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026031310015434700_ref14","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026031310015434700_ref15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2026031310015434700_ref16","doi-asserted-by":"publisher","first-page":"1196793","DOI":"10.3389\/fimmu.2023.1196793","article-title":"Severe and fatal adverse events of immune checkpoint inhibitor combination therapy in patients with metastatic renal cell carcinoma: a systematic review and meta-analysis","volume":"14","author":"Feng","year":"2023","journal-title":"Front Immunol"},{"key":"2026031310015434700_ref17","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/jjco\/hyae045","article-title":"Real-world treatment trends for patients with advanced prostate cancer and renal cell carcinoma and their cost\u2014a survey in Japan","volume":"54","author":"Osawa","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"2026031310015434700_ref18","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1038\/s41591-022-02029-1","article-title":"Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access","volume":"28","author":"Hirsch","year":"2022","journal-title":"Nat Med"},{"key":"2026031310015434700_ref19","doi-asserted-by":"publisher","first-page":"102181","DOI":"10.1016\/j.clgc.2024.102181","article-title":"Phase II trial of intermittent therapy in patients with metastatic renal cell carcinoma treated with front-line ipilimumab and nivolumab","volume":"22","author":"Ornstein","year":"2024","journal-title":"Clin Genitourin Cancer"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/3\/352\/65666197\/hyaf190.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/3\/352\/65666197\/hyaf190.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T14:01:59Z","timestamp":1773410519000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/3\/352\/8362157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":19,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,12,1]]},"published-print":{"date-parts":[[2026,3,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf190","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,12,1]]}}}